Abivax Temporarily Halts Share Trading on Euronext Paris Market
Abivax SA, a prominent clinical-stage biotechnology company, has made a significant announcement regarding its ordinary shares trading status on Euronext Paris. The Company focuses on developing innovative therapeutics that utilize the body’s natural regulatory mechanisms to adjust the immune response effectively. With an emphasis on chronic inflammatory diseases, Abivax's mission is to improve patient outcomes through cutting-edge science.
Today, Abivax confirmed that, at its request, trading of its shares will be temporarily halted starting from the opening of the market. This strategic move is related to the Company’s ongoing public offering of American Depositary Shares, where each share symbolizes one ordinary share at a nominal value of €0.01. The cessation of trading will enable the Company to solidify investor allocations and announce the pricing details of this offering.
The suspension of trading is anticipated to last until Abivax releases further updates. Market activities are expected to recommence later in the day, although specific timings will depend on the Company's announcements.
Company Overview
Headquartered in France and the United States, Abivax is making remarkable strides in biotechnology. The Company is at the forefront of developing pioneering drugs, with its lead candidate, obefazimod (ABX464), currently undergoing Phase 3 clinical trials targeting moderately to severely active ulcerative colitis. This disease represents a significant challenge for patients, and advancements in treatment options are crucial for improving their quality of life.
Research and Development Focus
Abivax is dedicated to researching innovative treatments by leveraging its understanding of the immune system's regulatory mechanisms. Their approach aims not only to treat symptoms but also to achieve long-lasting remission in patients with chronic inflammatory conditions.
Investor Relations
Patrick Malloy, the point of contact for investor relations at Abivax, is readily available for any inquiries. He can be reached via email at patrick.malloy@abivax.com or by phone at +1 847 987 4878. Abivax urges investors and stakeholders to keep up with their announcements for the latest updates regarding this pivotal moment for the Company.
Conclusion and Future Outlook
The temporary trading halt on Euronext Paris is a significant development for Abivax, reflecting the Company’s dynamic approach to its public offering and ensuring all investor allocations are properly managed. The biomedical landscape is constantly evolving, and Abivax is strategically positioned to play a vital role in the future of chronic disease treatment. As the market prepares for the resumption of trading, stakeholders should stay informed about updates from Abivax that will shape the next steps for its innovative therapeutic offerings.
Frequently Asked Questions
What caused the trading halt of Abivax shares?
The halt was requested by the Company to facilitate the confirmation of investor allocations related to its public offering of American Depositary Shares.
What is Abivax's focus as a biotechnology company?
Abivax focuses on developing therapeutics that modulate the immune response in patients suffering from chronic inflammatory diseases.
Who can I contact for more information about Abivax?
For investor relations, you can contact Patrick Malloy at patrick.malloy@abivax.com.
What is Abivax's lead drug candidate?
Abivax's lead drug candidate is obefazimod (ABX464), which is currently in Phase 3 clinical trials for ulcerative colitis treatment.
When is trading expected to resume?
Although trading is currently halted, it is expected to resume later in the day, contingent on further announcements from Abivax.
